[P3] A

[P3-016-A] Protection due to a novel ready-to-use PCV-2d and Mycoplasma hyopneumoniae vaccine against an experimental PCV-2 infection

Roman KREJCI Krejci¹, *Philippe Mazerolles¹, Péter Trampus², Adam Toth², Tamás Szalai² (1. Ceva (France), 2. Ceva Phylaxia (Hungary))

Keywords:

Mycoplasma hyopneumoniae,PCV-2d,Vaccine